Cognitive & Metabolic

Tirzepatide (Research Grade)

Tirzepatide research reference material supplied as freeze-dried powder for laboratory and preclinical studies.

≥99%Purity

LyophilizedForm

50mg×10 vialsPackaging

Chat on WhatsApp

For Research Use Only. Not for human consumption, food, or cosmetic use. These products have not been evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease.

Ships from multiple warehouses — typically 2–5 working days to most destinations. Cold-chain insulated packaging where required.

No published pricing. Available on request via WhatsApp. Volume and academic pricing is available for qualified research institutions.

Specifications

Sequence	39 amino-acid dual GIP/GLP-1 receptor agonist analogue
CAS Number	2023788-19-2
Molecular Formula	C₂₂₅H₃₄₈N₄₈O₆₈
Molecular Weight	≈ 4811.5 g/mol
Purity	≥ 99% (HPLC)
Appearance	White to off-white lyophilized powder
Solubility	Soluble in sterile water or bacteriostatic water for research use
Storage	-20°C, protect from light; after reconstitution 2–8°C
Shelf Life	24 months lyophilized from date of manufacture

Detail Images

Vial cap and seal detail — Vial cap & seal detail

Multiple research vials — Multi-vial overview

Analytical balance in a laboratory — Lab usage context

Researchers reviewing analytical data — Analytical workflow

Research Applications

Metabolic models

In vitro and animal metabolic disease research contexts.

Receptor signaling

Dual GIP/GLP-1 engagement and downstream cascades.

Formulation

Reconstitution, stability and delivery studies.

Quality Assurance & COA

Each batch passes HPLC purity verification and mass-spectrometry identity confirmation before release. A downloadable COA is provided with every order, including:

Batch number — traceable to synthesis lot
Purity — ≥99% by HPLC
Identity — confirmed by MS
Assay & appearance — documented per specification

Researchers can request batch-specific analytical data on WhatsApp.

Handling & Storage

Store lyophilized powder at -20°C, protected from light.
After reconstitution, keep at 2–8°C and use within the study window.
Reconstitute with a suitable sterile diluent for research use only.
Avoid repeated freeze–thaw cycles.

Selected Research References

Published literature informing Tirzepatide research (peer-reviewed, DOI-indexed):

Rosenstock J, et al. Tirzepatide in type 2 diabetes (SURPASS-1). Lancet. 2021. doi:10.1016/S0140-6736(21)01324-6
Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP/GLP-1 co-agonist. Cardiovasc Diabetol. 2022.

References are provided for research context only. No medical or therapeutic claims are made.

Batch & Traceability

Every vial carries a batch code linked to its COA and synthesis record, supporting reproducible, auditable research.

Product FAQ

Single research-grade specification: 50mg × 10 vials. Custom quantities available on request via WhatsApp.

Yes. Message us on WhatsApp with the batch you need and we will share the analytical summary.

From regional warehouses, 2–5 working days, with cold-chain insulated packaging where required.

Research Description

Tirzepatide is a 39-amino-acid peptide incorporating a C20 fatty diacid moiety, engineered as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. In published preclinical and clinical literature it demonstrates concurrent engagement of both incretin pathways. All descriptions are for research context only and make no medical claims.

Dual GIP / GLP-1 receptor activation — referenced in SURPASS and SURMOUNT trial literature.
Half-life ≈ 5 days (published pharmacokinetic data).
Supplied as a research reference material for receptor signaling and metabolic modeling studies.

Peptide Science

Tirzepatide Research Peptide: A Scientific Overview of the Dual GIP/GLP-1 Receptor Agonist

A research overview of Tirzepatide, a 39-aa dual GIP/GLP-1 receptor agonist peptide: chemical profile, mechanism, handling & COA. For lab research only.